Strides Pharma Q2 FY27 Revenue Rises 17% to ₹1,430 Crore as Ex-US Markets Overtake US Business for the First Time
Strides Pharma Science grew Q2 FY27 revenue 17% to ₹1,429.7 crore. Ex-US markets rose 31% to ₹696 crore, passing the US business (₹686 crore, +9%) in quarterly revenue for the first time, while EBITDA crossed ₹250 crore and margins eased to 17.6%.
